AHB-137 for Chronic Hepatitis B

(ASPIRE-202 Trial)

This trial tests a new treatment called AHB-137 for individuals with chronic hepatitis B, a liver infection caused by the hepatitis B virus. The researchers aim to evaluate the treatment's effectiveness and safety for those who have been on the same hepatitis B medication for at least six months. Participants may receive one of two dosing plans, regimen A or B. This trial may suit individuals who have managed hepatitis B with medication for over six months. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

You may need to stop taking your current nucleos(t)ide analog (NA) therapy if certain criteria are met during the trial. The protocol does not specify about other medications, so it's best to discuss your specific situation with the trial team.

Research has shown that AHB-137 is safe, based on previous studies. Patients tolerated the treatment well, with no serious side effects linked to the drug. One study noted that AHB-137 was well-received during both the treatment and follow-up periods, with no major problems reported. Additionally, the treatment was safe and behaved predictably in the body. These findings support its continued development for treating chronic hepatitis B.¹²³⁴⁵

Unlike the standard treatments for chronic hepatitis B, which often involve antiviral medications like tenofovir or entecavir that aim to suppress the virus, AHB-137 is a novel therapeutic that may offer something different. Researchers are excited about AHB-137 because it targets the virus with a potentially new mechanism of action, possibly offering improved efficacy or reduced side effects. This treatment is being explored in two different dosing regimens, providing insights into its optimal use. The hope is that AHB-137 could offer a more effective or tolerable option for patients battling this chronic condition.

Research has shown that AHB-137 may help treat chronic hepatitis B (CHB). One study found that after 24 weeks of treatment with AHB-137, 30% of patients achieved a "functional cure," meaning the virus was no longer detectable. Another study reported that after 16 weeks, all patients had very low levels of the virus. AHB-137 also effectively reduces viral DNA and surface antigens, which indicate infection. In this trial, participants will receive AHB-137 according to different dosing regimens in separate arms. These findings suggest AHB-137 could be a promising new option for managing CHB.⁴⁵⁶⁷⁸